Researchers at the Icahn School of Medicine at Mount Sinai have discovered how genetics can affect the success of venetoclax, ...
Janssen Research & Development was granted FDA orphan designation for a treatment of multiple myeloma, according to a post to the agency’s ...
A quadruplet regimen is now the preferred first-line treatment for multiple myeloma in both transplant-eligible and ...
Tyler Sandahl, PharmD, of Mayo Clinic, and Michael Byrne, DO, of Tennessee Oncology, discuss practical advice for bringing ...
GlobalData on MSN2d
GSK eyes up combo approval for previously withdrawn myeloma drugThe US Food and Drug Administration (FDA) is expected to make a Prescription Drug User Fee Act (PDUFA) decision by mid-2025.
Zacks.com on MSN1d
FDA Accepts GSK's BLA for Blenrep Combos in Multiple MyelomaGSK plc GSK announced that the FDA accepted its biologics license application (BLA) seeking approval for the Blenrep ...
Cesar Rodriguez, MD, discussed several key aspects of talquetamab use in the treatment of relapsed/refractory multiple ...
News Medical on MSN13d
Interactive atlas unveils immune changes in multiple myelomaMultiple Myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...
A treatment approach harnessing bispecific antibodies to target cancerous cells unlocks new possibilities for patients, says ...
Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...
MedPage Today on MSN9d
The Evolving Role of MRD in Managing Multiple Myeloma"MRD testing has revolutionized our approach to multiple myeloma, allowing us to detect even the smallest traces of cancer ...
Previously, he served on the board for the Greater Pinebelt Community Foundation and participated in Sanofi’s Multiple Myeloma Journey Partners Program. Mr. Oliver aspires to become a disruptor—to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback